Vertex Pharmaceuticals' stock saw a significant increase following the release of promising clinical trial results for its chronic kidney disease drug, povetacicept. The drug demonstrated a 52% reduction in proteinuria in patients with IgA nephropathy over 36 weeks. These positive outcomes suggest a potential new treatment for a condition that progressively damages the kidneys.